{"id":"W2577289848","doi":"10.1182/blood.v112.11.865.865","title":"Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Medicine; Multiple myeloma; Proteasome inhibitor; Population; Lenalidomide; Phases of clinical research; Internal medicine; Adverse effect; Gastroenterology; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002604346,0.001419326,0.001437691,0.0003538135,0.0005264944,0.0006697736,0.0006305463,0.0009968836,0.002681206],"category_scores_gemma":[0.001376422,0.000491322,0.0007280664,0.0002808925,0.0008472205,0.0006608199,0.0003181284,0.002641252,0.0006684421],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008678706,"about_ca_system_score_gemma":0.001023236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001141097,"about_ca_topic_score_gemma":0.002232079,"domain_scores_codex":[0.9992926,0.0004201124,0.00003121196,0.00007762328,0.00005599303,0.000122411],"domain_scores_gemma":[0.9987376,0.0003496312,0.0001633324,0.00007640079,0.00007718558,0.0005957944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5397169,0.11871,0.04585677,0.0007934658,0.001310411,0.001060966,0.001103142,0.005575345,0.1308133,0.0002900591,0.00721397,0.1475557],"study_design_scores_gemma":[0.234258,0.6822898,0.06938056,0.00003150598,0.0004988399,0.0006677355,0.0001091614,0.001762507,0.008035642,0.000167604,0.00276534,0.00003330667],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958802,0.0007279361,0.0003695019,0.0003202332,0.00002847068,0.0008969988,0.0006811764,0.00006519199,0.001030239],"genre_scores_gemma":[0.9948046,0.0003477742,0.0008092459,0.0004548094,0.00008579185,0.0006700441,0.001750838,0.00002173343,0.001055232],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002681206,"threshold_uncertainty_score":0.01377326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0779266594997658,"score_gpt":0.3478634319597014,"score_spread":0.2699367724599356,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}